Stay updated with breaking news from John Strickler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amgen Inc. (NASDAQ:NASDAQ:AMGN) European Society for Medical Oncology Annual Congress 2022 Conference Call September 12, 2022 01:30 PM ET Company Participants David Reese - Executive Vice...
Seagen recently presented positive pivotal Phase II data from its trial of Tukysa (tucatinib) in combination with trastuzumab in HER2-positive metastatic colorectal cancer.
Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance.
The MTB expansion will initially focus on patients with lung and thyroid cancers in several rural counties in North Carolina.
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS...